
    
      This phase 2 study using atezolizumab and bevacizumab aims to study the objective tumor
      response in women with recurrent endometrial cancer. Drugs will be administered via IV every
      21 days until disease progression, unacceptable toxicity, or loss of clinical benefit as
      determined by investigator. Subjects will receive routine cancer care as well as tests and
      procedures required for the purposes of this study. It is expected this combination will be
      produce an anti-cancer effect with manageable toxicities in this patient population.
    
  